PMID- 22994157
OWN - NLM
STAT- MEDLINE
DCOM- 20131104
LR  - 20190116
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 54
IP  - 5
DP  - 2013 May
TI  - Genomic arrays in chronic lymphocytic leukemia routine clinical practice: are we 
      ready to substitute conventional cytogenetics and fluorescence in situ 
      hybridization techniques?
PG  - 986-95
LID - 10.3109/10428194.2012.731598 [doi]
AB  - Chronic lymphocytic leukemia (CLL) is characterized by a highly variable clinical 
      course. Del(11q) and del(17p), routinely studied by conventional G-banding 
      cytogenetics (CGC) and fluorescence in situ hybridization (FISH), have been 
      related to progression and shorter overall survival. Recently, array-based 
      karyotyping has gained acceptance as a high-resolution new tool for detecting 
      genomic imbalances. The aim of the present study was to compare genomic arrays 
      with CGC and FISH to ascertain whether the current techniques could be 
      substituted in routine procedures. We analyzed 70 patients with CLL using the 
      Cytogenetics Whole-Genome 2.7M Array and CytoScan HD Array (Affymetrix), CGC and 
      FISH with the classical CLL panel. Whereas 31.4% and 68.6% of patients presented 
      abnormalities when studied by CGC and FISH, respectively, these rates increased 
      when arrays were also analyzed (78.6% and 80%). Although abnormality detection is 
      higher when arrays are applied, one case with del(11q) and three with del(17p) 
      were missed by genomic arrays due to their limited sensitivity. We consider that 
      the complete substitution of CGC and FISH by genomic arrays in routine 
      laboratories could negatively affect the management of some patients harboring 
      11q or 17p deletions. In conclusion, genomic arrays are valid to detect known and 
      novel genomic imbalances in CLL, but should be maintained as a complementary tool 
      to the current techniques.
FAU - Puiggros, Anna
AU  - Puiggros A
AD  - Programa de Recerca en Cancer, Grup de Recerca Translacional en Neoplasies 
      Hematologiques (GRETNHE), IMIM-Hospital del Mar, Barcelona, Spain.
FAU - Puigdecanet, Eulalia
AU  - Puigdecanet E
FAU - Salido, Marta
AU  - Salido M
FAU - Ferrer, Ana
AU  - Ferrer A
FAU - Abella, Eugenia
AU  - Abella E
FAU - Gimeno, Eva
AU  - Gimeno E
FAU - Nonell, Lara
AU  - Nonell L
FAU - Herranz, Maria Jose
AU  - Herranz MJ
FAU - Galvan, Ana Belen
AU  - Galvan AB
FAU - Rodriguez-Rivera, Maria
AU  - Rodriguez-Rivera M
FAU - Melero, Carme
AU  - Melero C
FAU - Pairet, Silvia
AU  - Pairet S
FAU - Bellosillo, Beatriz
AU  - Bellosillo B
FAU - Serrano, Sergi
AU  - Serrano S
FAU - Florensa, Lourdes
AU  - Florensa L
FAU - Sole, Francesc
AU  - Sole F
FAU - Espinet, Blanca
AU  - Espinet B
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20121016
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Chromosome Aberrations
MH  - Chromosome Banding
MH  - *Comparative Genomic Hybridization
MH  - DNA Copy Number Variations
MH  - Female
MH  - *Genomics/methods
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*diagnosis/genetics
MH  - Loss of Heterozygosity
MH  - Male
MH  - Middle Aged
EDAT- 2012/09/22 06:00
MHDA- 2013/11/05 06:00
CRDT- 2012/09/22 06:00
PHST- 2012/09/22 06:00 [entrez]
PHST- 2012/09/22 06:00 [pubmed]
PHST- 2013/11/05 06:00 [medline]
AID - 10.3109/10428194.2012.731598 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2013 May;54(5):986-95. doi: 10.3109/10428194.2012.731598. Epub 
      2012 Oct 16.